This inventor holds 1 USPTO granted patent. Top assignee: Bioiberica, S.a.. Active years: 1992.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1992
Title: The Innovative Contributions of Alberto D. Nusimovich
Introduction
Alberto D. Nusimovich is a notable inventor based in Andreu de Llavaneres, Spain. He has made significant contributions to the field of biochemistry, particularly in the development of oligosaccharide fractions with antithrombotic properties. His work has implications for medical treatments and drug development.
Latest Patents
Nusimovich holds a patent for the "Production of oligosaccharide fractions having antithrombotic properties." This innovative process involves creating an oligosaccharide fraction from commercially available heparin solutions containing between 1 to 10% heparin. The resulting oligosaccharide fraction exhibits antithrombotic activity, high bioavailability, minimal toxic effects, and a reduced risk of hemorrhage. The process includes ultrafiltration, phase partitioning, and the formation of a heparin-quaternary ammonium complex, ultimately isolating the oligosaccharide fraction through various steps.
Career Highlights
Nusimovich is associated with Bioiberica, S.A., a company that focuses on the research and development of biopharmaceuticals. His work at Bioiberica has allowed him to contribute to advancements in therapeutic solutions, particularly in the area of anticoagulants.
Collaborations
Throughout his career, Nusimovich has collaborated with esteemed colleagues such as Francisco J. Vila and Pedro T. Gomis. These collaborations have fostered a productive environment for innovation and research in the field of biochemistry.
Conclusion
Alberto D. Nusimovich's contributions to the field of biochemistry, particularly through his patented process for producing oligosaccharide fractions, highlight his role as an influential inventor. His work continues to impact medical science and therapeutic development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile